Universität zu Köln

Borchmann, Sven, von Tresckow, Bastian and Engert, Andreas (2016). Current developments in the treatment of early-stage classical Hodgkin lymphoma. Curr. Opin. Oncol., 28 (5). S. 377 - 384. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1531-703X

Full text not available from this repository.

Abstract

Purpose of review After presenting the current treatment recommendations for early-stage Hodgkin lymphoma, we give an overview on recently published clinical trials in this setting. Furthermore, the potential influence of current trials on the treatment of early-stage Hodgkin lymphoma and integration of newly emerging drugs into treatment protocols will be discussed. Recent findings Trials attempting treatment de-escalation and omission of radiotherapy on the basis of early interim PET-scans have been disappointing so far, but results of some large trials employing this strategy are still awaited. In contrast, a more defensive strategy of starting treatment with less aggressive doxorubicine, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy and intensifying treatment in early interim PET-positive patients has shown encouraging results. New drugs such as brentuximab vedotin and immune checkpoint inhibitors have shown promising results in relapsed and refractory Hodgkin lymphoma. Clinical trials of brentuximab vedotin in early-stage Hodgkin lymphoma have been initiated. Additionally, biomarker-based treatment de-escalation might be a possible route for future improvements. Summary The challenge for future clinical research in early-stage Hodgkin lymphoma is to continue to cure the majority of patients with first-line treatment while reducing long-term toxicity. New strategies to achieve that goal are currently being developed and will further refine treatment of early-stage Hodgkin lymphoma.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Borchmann, Sven UNSPECIFIED UNSPECIFIED UNSPECIFIED von Tresckow, Bastian UNSPECIFIED UNSPECIFIED UNSPECIFIED Engert, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-264948
DOI:	10.1097/CCO.0000000000000314
Journal or Publication Title:	Curr. Opin. Oncol.
Volume:	28
Number:	5
Page Range:	S. 377 - 384
Date:	2016
Publisher:	LIPPINCOTT WILLIAMS & WILKINS
Place of Publication:	PHILADELPHIA
ISSN:	1531-703X
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language STEM-CELL TRANSPLANTATION; BRENTUXIMAB VEDOTIN; PHASE-II; FDG-PET; TRIAL; RISK; DISEASE; RELAPSE; RADIOTHERAPY; INTENSITY Multiple languages Oncology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/26494